Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 2: 350 - 359

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.02.008

Original Articles

Identification and verification of key genes related to oxidative stress in type 2 diabetes and screening of candidate drugs from Traditional Chinese Medicine

  • HU Jingnan ,
  • LIAO Man ,
  • XI Zhongwen ,
  • SONG Jing ,
  • WANG Yining ,
  • HE Tao
Expand
  • 1 Department of Pharmacy, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang 050011, China
    2 Department of Analysis and Testing Center, Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation, Shijiazhuang 050011, China
    3 Department of Anesthesiology, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang 050011, China
HE Tao, Department of Anesthesiology, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang 050011, China. zest2030@163.com; Telephone: +86-311-69095606

Received date: 2025-02-05

  Accepted date: 2025-06-06

  Online published: 2026-04-04

Supported by

Scientific Research Project of Hebei Administration of Traditional Chinese Medicine: Study on the Pharmacodynamic Material Basis and Mechanism of Cyanotis arachnoidea in the Treatment of Type 2 Diabetes Mellitus(2024009)

Fold

Abstract

OBJECTIVE: To identify oxidative stress (OS)-related genes involved in type 2 diabetes mellitus (T2DM) and screen potential Traditional Chinese Medicine (TCM) candidates for therapeutic use.

METHODS: Gene expression data from the GSE23343 dataset were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between healthy and T2DM patients were identified. Weighted gene co-expression network analysis (WGCNA) was performed to select modules highly correlated with clinical traits, and core genes within these modules were identified. OS-related genes were retrieved from the GeneCards database, and the overlapping DEGs, WGCNA genes, and OS-related genes were considered as hub genes in OS-related T2DM. These hub genes were validated in GSE15653 dataset. Potential TCMs were identified by mapping the hub genes to the Coremine Medical database. In vivovalidation was performed using a T2DM rat model established by a high-fat diet and streptozotocin injection. The effects of Wedelolactone were evaluated by assessing gene expression viareal-time quantitative reverse transcription PCR (qRT-PCR) and Western blot, alongside metabolic and liver function parameters, including fasting blood glucose, glycated serum protein, insulin resistance, and lipid profiles.

RESULTS: A total of 394 DEGs (136 up-regulated and 258 down-regulated DEGs.) were identified in the GSE23343 cohort. WGCNA results showed that the turquoise module (cor = -0.56, P = 0.02) and the brown module (cor = 0.66, P = 0.004) were the most correlated with T2DM. Six hub genes [interleukin 33 (IL33), S100 calcium binding protein A8 (S100A8), Golgi membrane protein 1 (GOLM1), small nuclear ribonucleoprotein U1 subunit 70 (SNRNP70), hepatocyte growth factor activator (HGFAC), and oxidative stress induced growth inhibitor 1 (OSGIN1)] were identified, with IL33, S100A8, and GOLM1 being up-regulated, and SNRNP70, HGFAC, and GOLM1 being down-regulated. These genes distinguished T2DM from healthy controls with AUC values greater than 0.8. Experimental verification using a T2DM rat model confirmed the expression patterns of the hub genes. In vivo data demonstrated that Wedelolactone significantly reduced oxidative stress, inflammation hepatic lipid accumulation, and improved metabolic parameters such as fasting blood glucose, glycated serum protein, and insulin resistance.

CONCLUSION: These findings highlight the critical roles of IL33, S100A8, GOLM1, SNRNP70, HGFAC, and OSGIN1 as biomarkers in OS-related T2DM and suggest that Wedelolactone may be a promising TCM-based therapeutic candidate for T2DM.

Key words： diabetes mellitus, type 2; oxidative stress; gene expression profiling; computational biology; medicine, Chinese traditional; Wedelolactone

Cite this article

HU Jingnan , LIAO Man , XI Zhongwen , SONG Jing , WANG Yining , HE Tao . Identification and verification of key genes related to oxidative stress in type 2 diabetes and screening of candidate drugs from Traditional Chinese Medicine[J]. Journal of Traditional Chinese Medicine, 2026 , 46(2) : 350 -359 . DOI: 10.19852/j.cnki.jtcm.2026.02.008

References

1. Zhao YY, Xing HC, Wang XM, et al. Management of diabetes mellitus in patients with chronic liver diseases. J Diabetes Res 2019; 2019: 6430486.
2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 2019; 157: 107843.
3. Zhu FY, Dong ZW, Zhu WY, Liu ZQ. Advances in anti-diabetes drugs and their synthesis. Fa Jiao Ke Ji Tong Xun 2016; 45: 175-81.
4. Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? J Cell Biochem 2017; 118: 3577-85.
5. Banik S, Ghosh A. The association of oxidative stress biomarkers with type 2 diabetes mellitus: a systematic review and Meta-analysis. Health Sci Rep 2021; 4: e389.
6. Gjorgjieva M, Mithieux G, Rajas F. Hepatic stress associated with pathologies characterized by disturbed glucose production. Cell Stress 2019; 3: 86-99.
7. Klisic A, Isakovic A, Kocic G, et al. Relationship between oxidative stress, inflammation and dyslipidemia with fatty liver index in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2018; 126: 371-8.
8. Bigagli E, Lodovici M. Circulating oxidative stress biomarkers in clinical studies on type 2 diabetes and its complications. Oxid Med Cell Longev 2019; 2019: 5953685.
9. Ye HW, Wang RX, Wei JJ, Wang Y, Zhang XF, Wang LH. Bioinformatics analysis identifies potential ferroptosis key gene in type 2 diabetic islet dysfunction. Front Endocrinol (Lausanne) 2022; 13: 904312.
10. Peng SH, Liu L, Xie ZY, et al. Chinese herbal medicine for type 2 diabetes mellitus with nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Front Pharmacol 2022; 13: 863839.
11. Wang Y, Dai ZL, Wang Q, et al. Clinical application of Traditional Chinese Medicine therapy for type 2 diabetes mellitus: an evidence map. Evid Based Complement Alternat Med 2022; 2022: 2755332.
12. Bhatti JS, Sehrawat A, Mishra J, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radic Biol Med 2022; 184: 114-34.
13. Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5: 194-222.
14. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
15. Aleksunes LM, Manautou JE. Emerging role of Nrf 2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 2007; 35: 459-73.
16. Hurtado-Carneiro V, Dongil P, Perez-Garcia A, Alvarez E, Sanz C. Preventing oxidative stress in the liver: an opportunity for GLP-1 and/or PASK. Antioxidants (Basel) 2021; 10: 2028.
17. Chupradit S, Bokov D, Zamanian MY, Heidari M, Hakimizadeh E. Hepatoprotective and therapeutic effects of resveratrol: a focus on anti-inflammatory and antioxidative activities. Fundam Clin Pharmacol 2022; 36: 468-85.
18. Mukai E, Fujimoto S, Inagaki N. Role of reactive oxygen species in glucose metabolism disorder in diabetic pancreatic beta-cells. Biomolecules 2022; 12: 1228.
19. Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of diabetes-iInduced liver damage: the role of oxidative stress and inflammation. Sultan Qaboos Univ Med J. 2016; 16: e132-41.
20. Haythorne E, Lloyd M, Walsby-Tickle J, et al. Altered glycolysis triggers impaired mitochondrial metabolism and mTORC 1 activation in diabetic beta-cells. Nat Commun 2022; 13: 6754.
21. Bogan JS. Ubiquitin-like processing of TUG proteins as a mechanism to regulate glucose uptake and energy metabolism in fat and muscle. Front Endocrinol (Lausanne) 2022; 13: 1019405.
22. Verma G, Bowen A, Gheibi S, et al. Ribosomal biogenesis regulator DIMT1 controls beta-cell protein synthesis, mitochondrial function, and insulin secretion. J Biol Chem 2022; 298: 101692.
23. Boodhoo K, Vlok M, Tabb DL, Myburgh KH, van de Vyver M. Dysregulated healing responses in diabetic wounds occur in the early stages postinjury. J Mol Endocrinol 2021; 66: 141-55.
24. Tonacci A, Quattrocchi P, Gangemi S. IL33/ST 2 axis in diabetic kidney disease: a literature review. Medicina (Kaunas) 2019; 55: 50.
25. Lu JL, Liang Y, Zhao JJ, Meng HY, Zhang XJ. Interleukin-33 prevents the development of autoimmune diabetes in NOD mice. Int Immunopharmacol 2019; 70: 9-15.
26. Lin J, Lan Y, Xiang DC, et al. IL-33 promotes pancreatic beta-cell survival and insulin secretion under diabetogenic conditions through PPARgamma. Eur J Pharmacol 2023; 959: 176059.
27. Yi XM, Lian H, Li S. Signaling and functions of interleukin-33 in immune regulation and diseases. Cell Insight 2022; 1: 100042.
28. De Jesus A, Keyhani-Nejad F, Pusec CM, et al. Hexokinase 1 cellular localization regulates the metabolic fate of glucose. Mol Cell 2022; 82: 1261-77 e9.
29. Rodrigues RM, He Y, Hwang S, et al. E-selectin-dependent inflammation and lipolysis in adipose tissue exacerbate steatosis-to-NASH progression via S100A8/9. Cell Mol Gastroenterol Hepatol 2022; 13: 151-71.
30. Fang XY, Miao RY, Wei JH, Wu HR, Tian JX. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder. Comput Struct Biotechnol J 2022; 20: 5935-51.
31. Zheng KI, Liu WY, Pan XY, et al. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Res Care 2020; 8: e001174.
32. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol 2020; 11: 1582.
33. Yan S, Lu W, Zhou J, et al. Aqueous extract of Scrophularia ningpoensis improves insulin sensitivity through AMPK-mediated inhibition of the NLRP3 inflammasome. Phytomedicine 2022; 104: 154308.
34. Yuan HL, Ouyang S, Yang RN, et al. Osthole alleviated diabetic neuropathic pain mediated by the P2X(4) receptor in dorsal root ganglia. Brain Res Bull 2018; 142: 289-96.
35. Lee D, Lee DH, Choi S, Lee JS, Jang DS, Kang KS. Identification and isolation of active compounds from astragalus membranaceus that improve insulin secretion by regulating pancreatic beta-cell metabolism. Biomolecules 2019 ; 9: 618.
36. Wang P, Liu Y, Zhang T, et al. Effects of root extract of morinda officinalis in mice with high-fat-diet/streptozotocin-induced diabetes and C2C12 myoblast differentiation. ACS Omega 2021; 6: 26959-68.
Options
Outlines

/

〈 〉